

# Maria Sicilia

3535 Burning Bush Rd · Bloomfield Hills, MI 48301  
siciliam@umich.edu · (248) 309-9926

<b>EDUCATION</b>	<b>UNIVERSITY OF MICHIGAN</b> <b>College of Engineering, Class of 2025</b> BSE, Biomedical Engineering   Biotechnology & Pharmaceutical Engineering Track   CS Minor <ul style="list-style-type: none"><li>• GPA: 3.87/4.0, Dean's List, University Honors   800 SAT Math II, 800 SAT Biology-M</li><li>• Relevant Coursework: Biopharmaceutical Engineering; Immuno-engineering; Mechanobiology; Biomechanics; Automated Science; Biophysical Chemistry and Thermodynamics; Multivariable &amp; Vector Calculus; Differential Equations; Programming &amp; Data Structures; Process &amp; Throughput Optimization</li><li>• Michigan Interactive Investments Club Senior Analyst, Genes in Disease and Research Club</li><li>• 2nd ENGAGE UIC Case Competition 2022 for Burford Capital Pitch</li></ul>	<b>Ann Arbor, MI</b>
<b>EXPERIENCE</b> <b>2022-2023</b>	<b>MERCY BIOANALYTICS</b> <b>Project Manager   Early Cancer Detection Startup</b> <ul style="list-style-type: none"><li>• Worked with Chief Scientific Officer and Chief of Staff to create quarterly investor update materials and pitch deck simplifying explanation of extracellular vesicle superiority in early liquid biopsy cancer detection, creating regulatory precedent timelines used by board to evaluate foray into future cancer testing types</li><li>• Used CPT/HCPCS code databases to calculate historic yearly Medicare, Medicaid, and private co-pay spend for top cancer indications with historical adherence to US Preventive Services Task Force guidelines, running regression of spend vs. similar test technology company round valuations at key regulatory timepoints, resulting in internal pre-money Series A benchmark valuation guide at ~\$100m (\$41m raised, closed 4/3/23)</li><li>• Combined above approach with direct comparison against Delfi Diagnostics' Series B (Mercy having superior test quality, lower COGS, better capital efficiency, similarly strong board) in addition to projecting internal cash flows for biopharma/testing revenue with Cytoc Corporation and Exact Sciences founder's advice</li></ul>	<b>Natick, MA</b>
<b>2021-2022</b>	<b>PARADIGM OPPORTUNITIES</b> <b>Junior Analyst   Healthcare Hedge Fund</b> <ul style="list-style-type: none"><li>• Attended Alliance Global Partners Biotech conference, interviewing E-board &amp; founders of 7 biotech, medical device, and pharmaceutical companies; interpreted science of patents and research to present to investment team, working with healthcare hedge fund founder to evaluate medical technologies</li><li>• Created database of top 106 world biodefense threats, noting interested agencies, impacted area, threat classification, as well as notable related grant funding, research developments, regulatory changes, and outbreak data; narrowed to top 15 based on quality/stage before presenting potential acquisition target molecules for Alphavirus Equine Encephalitis to pharmaceutical company board meeting</li><li>• Diligenced pain imaging VC-stage company Lutroo based on patent filings and conversations with founding team, resulting in 500k convertible note Seed investment; made updated investor pitch deck to simplify explanation of PET radiotracer technology along with other additional marketing materials</li></ul>	<b>New York, NY</b>
<b>2021-2022</b>	<b>THREE CURVE CAPITAL</b> <b>Project Manager   Family Office</b> <ul style="list-style-type: none"><li>• Created investor database of 6,281 professionals at 1,669 VC, PE, family office, and angel firms tagged by niche to raise debt and equity capital for portfolio companies; semi-automated reach out with Google Script, improving efficiency from first raise spending 20+ hours manually sending 657 emails to set up meetings with 22 different firms to current taking 1 hour prep to send 1338 emails for 30+ meetings</li><li>• Made pitch materials for founders, set meetings with investors for several multi-million dollar raises, including Dashmote, Discourse Analytics (had capital lined up, chose to wait for market conditions), Immensity for Artists (\$2m), Mercy Bioanalytics (\$41m) &amp; Montana Technologies (ended up getting 9-figure manufacturing deal with the Saudis, recently reverse merged)</li></ul>	<b>Boston, MA</b>
<b>2019-2022</b>	<b>MIRCORE</b> <b>Education Committee Senior Leader, Computational Bio &amp; Biotech TA   Research Non-Profit</b> <ul style="list-style-type: none"><li>• Designed curriculum for Computational Biology, Biotechnology, and R Research camps, taught students biology concepts, coding in Unix and R to design RNAi biomedicine drugs using tools like MFold and RNAwizard; transitioned high school programs to an online setting, taking advantage of virtual change to recruit attendees, creating new miRcore chapters in Georgia, South Korea, Texas, Illinois, and more</li><li>• Taught R, Python, and applications to biology research, helping students in smaller groups with projects to generate graphics to present research, as well as how to code an AI-driven classification system to differentiate between tumor and control samples based on RNA expression values</li><li>• Oversaw recruitment and onboarding for miRcore's year-long volunteer program, resulting in 68 new recruits publishing abstracts in the Journal For Emerging Investigators</li></ul>	<b>Ann Arbor, MI</b>
<b>ADDITIONAL</b>	<ul style="list-style-type: none"><li>• Interests: tennis, golf, dogs (recently, cats), graphite and/or charcoal drawing, skiing, fly fishing</li><li>• Dante Alighieri Italian Society fellow, exchange at linguistic high school in Todi, Italy</li><li>• Past golf caddie, varsity team captain, all-state academic, and regional champion</li></ul>	